Target intelligence / Profile preview

Negatively charged membrane phospholipids (PS)

Target
PS
Molecular classification
Lipid, Phospholipid, Anionic lipid
01

Overview

Negatively charged membrane phospholipids, such as phosphatidylserine (PS), phosphatidylinositol, and phosphatidylglycerol, are essential lipid components that play critical roles in membrane structure and cell signaling (Birge et al., 2016, Cell Death & Differentiation). In healthy mammalian cells, these lipids are actively sequestered in the inner leaflet of the plasma membrane, but they become externalized on the surface of apoptotic cells and tumor-associated vascular endothelial cells (Ran and Thorpe, 2002, Int J Radiat Oncol Biol Phys). This surface exposure serves as a 'global' immunosuppressive signal in the tumor microenvironment, facilitating immune evasion (Birge et al., 2016). Therapeutic strategies, such as the monoclonal antibody bavituximab, target exposed PS to reverse this immunosuppression and induce antibody-dependent cellular cytotoxicity (Gerber et al., 2015, Clin Cancer Res). Additionally, anionic phospholipids are primary targets for certain antibiotics; for instance, daptomycin targets phosphatidylglycerol in bacterial membranes to cause depolarization (Pogliano et al., 2012, J Bacteriol). Viral envelopes also frequently expose PS, making them susceptible to PS-targeting agents that block viral entry or trigger immune clearance (Soares et al., 2008, Nat Rev Cancer).

Other names
Anionic phospholipidsAcidic phospholipidsPhosphatidylserinePhosphatidylinositolPhosphatidylglycerolPhosphatidic acidCardiolipin
02

Mechanism of action

Binding to externalized anionic phospholipids to trigger immune-mediated cell death (ADCC), disrupt membrane permeability, or inhibit viral entry.

03

Biological functions

Cell signalingApoptosisBlood coagulationMembrane traffickingCellular homeostasis
04

Disease associations

CancerInfectionAutoimmune diseaseInflammationCardiovascular disease
05

Safety considerations

Risk of thrombosisAntiphospholipid syndrome inductionNephrotoxicityNon-specific membrane disruption
06

Interacting drugs

Bavituximab

4 more in the full profile.

07

Biomarkers

Annexin V bindingAnti-phosphatidylserine antibodiesAnti-cardiolipin antibodies

Beyond the preview

Go deeper on Negatively charged membrane phospholipids (PS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Negatively charged membrane phospholipids (PS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call